Article
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Acta haematologica - 1 Jan 2022
Desikan Sai Prasad, Ravandi Farhad, Pemmaraju Naveen, Konopleva Marina, Loghavi Sanam, Jabbour Elias J, Daver Naval, Jain Nitin, Chien Kelly S, Maiti Abhishek, Montalban-Bravo Guillermo, Kadia Tapan M, Macaron Walid, DeLumpa Ricardo, Kwari Monica, Borthakur Gautam, Short Nicholas J
Abstract excerpt
INTRODUCTION: RAS pathway mutations are common mechanisms of resistance to acute myeloid leukemia (AML) therapies. Trametinib, an oral MEK inhibitor, has been shown to have single-agent activity in relapsed/refractory AML and preclinical synergy with venetoclax. METHODS: We conducted a single-center, open-label, phase 2 trial of the combination of azacitidine, venetoclax, and trametinib in patients with relapsed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.